News
Source-attributed headlines with timestamps and links to the companies and crypto markets they mention.
Latest Coverage
30 headlines
D-Wave Quantum received up to $100 million in funding from the U.S. Department of Commerce under the CHIPS and Science Act, causing its stock to rise 10.86%. However, the government also awarded similar $100 million grants to rival quantum companies Quantinuum and Rigetti Computing. GlobalFoundries received the largest award at $375 million, suggesting it may be the government's preferred champion rather than D-Wave.
The article argues that investors who aggressively buy during bear markets, rather than panic selling, build significantly more wealth over time. Using Warren Buffett's philosophy of maintaining cash reserves to deploy during market downturns, the piece demonstrates that a modest improvement in annual returns (from 10% to 11%) through strategic bear market investing could result in approximately one-third more wealth over 30 years. The key is maintaining discipline and a long-term perspective rather than attempting to time market peaks and troughs perfectly.
A Motley Fool analyst recommends the Vanguard Total International Stock ETF (VXUS) as a single $500 investment choice for September 2026, citing concerns about S&P 500 valuations driven by AI stocks. VXUS has delivered 26% returns over the past year and 19.8% annualized returns over three years. Vanguard research forecasts international stocks may outperform U.S. stocks by 1.2-2.2% annually over the next 30 years.
A class action lawsuit has been filed against Papa John's International, Inc. (NASDAQ: PZZA) alleging securities fraud. The complaint claims that company executives made materially false and misleading statements regarding the company's transformation efforts, market share losses, and competitive position during the period from August 7, 2025 to August 5, 2026. Investors who purchased Papa John's securities during this period are encouraged to join the case, with a lead plaintiff deadline of November 2, 2026.
A class action lawsuit has been filed against iTonic Holdings Ltd. (formerly Pheton Holdings Ltd.) alleging that the company made materially false and misleading statements regarding market manipulation schemes, fraudulent trading activity, and stock price inflation. The lawsuit covers investors who purchased shares between September 5, 2024 and July 29, 2025. The lead plaintiff deadline is September 29, 2026.
Citigroup analyst Yitchuin Wong initiates coverage on UiPath (NYSE:PATH) with a Buy rating and announces Price Target of $23.
Filed: 2026-09-08 AccNo: 0001326771-26-000145 Size: 456 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Citigroup analyst Ariel Rosa upgrades Old Dominion Freight Line (NASDAQ:ODFL) from Neutral to Buy and lowers the price target from $231 to $223.
Citigroup analyst Ariel Rosa upgrades C.H. Robinson Worldwide (NASDAQ:CHRW) from Neutral to Buy and lowers the price target from $196 to $185.
The Guidewire stock drop hit 20% after a Q4 earnings beat. See why soft FY27 guidance and a stretched valuation triggered the sell-off.
Citigroup analyst Eric Joseph initiates coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Buy rating and announces Price Target of $108.
Filed: 2026-09-08 AccNo: 0001663577-26-000262 Size: 280 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Thermo Fisher Scientific (NYSE:TMO) has outperformed the market over the past 15 years by 4.35% on an annualized basis producing an average annual return of 17.57%. Currently, Thermo Fisher Scientific has a market
Robinhood strikes a multiyear Crypto.com deal to add OG contracts and take minority stakes as its prediction-market business keeps growing.
Shopify (SHOP) fell nearly 8% as investors rotated away from high-multiple growth stocks despite strong Q2 earnings. Learn more.
AstraZeneca secured FDA approval for its breast cancer drug Etcamah and reported positive Phase 3 trial data for lung cancer and COPD.